



# Evrysdi in Egypt

The EDA named-patient coordination pathway — indicative 2026

RARE DISEASE · SPINAL MUSCULAR ATROPHY

## The clinical situation

Evrysdi (risdiplam) is an FDA-approved oral SMN2 splicing modifier for patients of all ages with spinal muscular atrophy (SMA), dosed once daily as a liquid solution reconstituted from powder. Manufactured by Genentech/Roche. Dose is weight-based for paediatric patients. Refrigerated shipment is required until reconstitution, then 64-day stability at room temperature once mixed.

### The pathway, 5 steps

- 1 Consultation & genetic confirmation.** Treating paediatric neurologist confirms SMN1 deletion / SMA diagnosis, motor-function baseline, and weight-based dose calculation.
- 2 Treating centre & prescription confirmed.** An Egyptian tertiary neuromuscular centre (Cairo, Alexandria) issues the prescription and commits to motor-function monitoring.
- 3 EDA named-patient / personal-import application.** Clinical rationale, prescription, genetic report, and product details are filed with the Egyptian Drug Authority for import clearance.
- 4 US-side sourcing & cold-chain logistics.** Reserve Meds coordinates product through our US-licensed DSCSA-compliant specialty wholesale partner; refrigerated shipment booked to arrive unmixed.
- 5 Reconstitution & dispensing.** Powder is reconstituted by the pharmacist at the treating centre and dispensed; refills coordinated on a 30-day cycle with periodic motor-function review.

### Indicative economics

**Reference US cash-pay range:** USD 100,000–340,000 per year drug-only, weight-based. Cold-chain logistics, EDA documentation, and concierge coordination are incremental. Full transparent quote at intake.

### Indicative first-fill timing

**7–14 days** from a complete EDA application to first-fill delivery, once cohort intake opens. Indicative — not guaranteed.

## Reserve Meds's role

**Sourcing.** US-licensed specialty wholesale partner, DSCSA chain-of-custody. **Documentation.** EDA named-patient package including weight-based dose calculation. **Logistics.** Cold-chain, temperature-monitored shipment coordination to the treating centre. **Concierge case lead.** Named point of contact for family and physician through the full process. **We are a coordinator** — not the prescriber, not the dispensing pharmacy. All clinical decisions remain with your treating neurologist.

**COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST**

**Join the Evrysdi × Egypt first-cohort waitlist.** *Our concierge reaches out as we open intake.*

[reservemed.com/access-guides/evrysdi-egypt.html](https://reservemed.com/access-guides/evrysdi-egypt.html)



SCAN TO JOIN

**Reserve Meds** · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

*Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.*

**reservemed.com** · [hello@reservemed.com](mailto:hello@reservemed.com) · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team